Lilly joins drugmakers probed by DOJ about PBMs

Eli Lilly today said it has joined a growing list of pharma companies to be asked by the Justice Department to cough up info on relationships with pharmacy benefits managers, the companies that negotiate prices and set reimbursement conditions.

Deep in its quarterly report filed today with the SEC, Lilly said it has “received a civil investigative demand from the U.S. Attorney’s Office for the Southern District of New York requesting documents and information relating to our contracts with, services performed by and payments to pharmacy benefit managers.” It said it was cooperating with the investigation.

In an email, Eli Lilly declined to comment beyond its filing.

It has not been clear what exactly the DOJ is looking for, although in the past drugmakers such as Novartis ($NVS) and AstraZeneca ($AZN) have agreed to pay fines and penalties to settle allegations they had offered a quid pro quo to PBMs for preferred formulary status.

Read the rest of the article here

by Eric Palmer at